{"id":"1-etanercept","safety":{"commonSideEffects":[{"rate":"37","effect":"Injection site reactions"},{"rate":"29","effect":"Upper respiratory tract infections"},{"rate":"12","effect":"Headache"},{"rate":"2-3","effect":"Serious infections"},{"rate":"0.1-0.5","effect":"Tuberculosis reactivation"},{"rate":"rare","effect":"Demyelinating disease"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Etanercept consists of the extracellular ligand-binding portion of the human TNF receptor II fused to the Fc region of human IgG1. It acts as a soluble TNF receptor that competitively inhibits TNF-α and TNF-β from binding to cell surface TNF receptors, thereby suppressing TNF-mediated inflammatory responses. This mechanism reduces the activation of immune cells and production of inflammatory mediators in autoimmune and inflammatory conditions.","oneSentence":"Etanercept is a TNF receptor fusion protein that binds and neutralizes tumor necrosis factor (TNF), a key inflammatory cytokine.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:55:53.054Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Rheumatoid arthritis"},{"name":"Psoriatic arthritis"},{"name":"Ankylosing spondylitis"},{"name":"Juvenile idiopathic arthritis"},{"name":"Plaque psoriasis"},{"name":"Crohn's disease"}]},"trialDetails":[{"nctId":"NCT06654882","phase":"PHASE3","title":"Trial of Sequential Medications AfteR TNFi Failure in Juvenile Idiopathic Arthritis","status":"RECRUITING","sponsor":"Duke University","startDate":"2026-01-09","conditions":"Polyarticular Course Juvenile Idiopathic Arthritis (JIA)","enrollment":400},{"nctId":"NCT03997786","phase":"PHASE2, PHASE3","title":"A Study of Tildrakizumab in Pediatric Subjects With Chronic Plaque Psoriasis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sun Pharmaceutical Industries Limited","startDate":"2020-01-15","conditions":"Moderate-to-severe Chronic Plaque Psoriasis","enrollment":135},{"nctId":"NCT03451851","phase":"PHASE3","title":"A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Subcutaneously Administered Guselkumab for the Treatment of Chronic Plaque Psoriasis in Pediatric Participants","status":"ACTIVE_NOT_RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2018-07-11","conditions":"Psoriasis","enrollment":120},{"nctId":"NCT05950724","phase":"EARLY_PHASE1","title":"RENAL: TNF-alpha Inhibitor for Improving Renal Dysfunction and Primary Graft Dysfunction After Lung Transplant","status":"ENROLLING_BY_INVITATION","sponsor":"Northwestern University","startDate":"2023-09-17","conditions":"Lung Transplant; Complications","enrollment":20},{"nctId":"NCT05305066","phase":"NA","title":"Stand UP to Rheumatoid Arthritis (SUPRA)","status":"RECRUITING","sponsor":"Marie Hudson, MD","startDate":"2023-02-01","conditions":"Rheumatoid Arthritis","enrollment":75},{"nctId":"NCT06075706","phase":"PHASE2","title":"Trial of Efficacy and Safety of MC0518 Versus Best Available Therapy in Participants With Steroid-Refractory Acute Graft Versus Host Disease","status":"ACTIVE_NOT_RECRUITING","sponsor":"medac GmbH","startDate":"2023-11-13","conditions":"Steroid-refractory Acute Graft-versus-host Disease","enrollment":48},{"nctId":"NCT01000441","phase":"PHASE4","title":"Rotation or Change of Biotherapy After First Anti-TNF Treatment Failure for Rheumatoid Arthritis","status":"COMPLETED","sponsor":"University Hospital, Strasbourg, France","startDate":"2009-12-23","conditions":"Rheumatoid Arthritis","enrollment":300},{"nctId":"NCT07352566","phase":"PHASE4","title":"Utilization of a Microdevice for Psoriasis and Atopic Dermatitis","status":"NOT_YET_RECRUITING","sponsor":"University of California, San Francisco","startDate":"2026-01-01","conditions":"Psoriasis, Atopic Dermatitis","enrollment":10},{"nctId":"NCT02987257","phase":"PHASE3","title":"NATIENS: Optimal Management and Mechanisms of SJS/TEN","status":"COMPLETED","sponsor":"Vanderbilt University Medical Center","startDate":"2023-03-21","conditions":"Stevens-Johnson Syndrome, Toxic Epidermal Necrolyses","enrollment":2},{"nctId":"NCT03792841","phase":"PHASE1","title":"Safety, Tolerability, Pharmacokinetics, and Efficacy of Acapatamab in Subjects With mCRPC","status":"TERMINATED","sponsor":"Amgen","startDate":"2019-02-05","conditions":"Metastatic Castration-resistant Prostate Cancer, Prostate Cancer","enrollment":212},{"nctId":"NCT05379322","phase":"PHASE3","title":"The Use of Synovial Biopsies in Predicting Response to Biologic Therapy in Rheumatoid Arthritis Patients","status":"WITHDRAWN","sponsor":"Abu Dhabi Stem Cells Center","startDate":"2023-03-01","conditions":"Rheumatoid Arthritis","enrollment":""},{"nctId":"NCT06392074","phase":"PHASE1","title":"A Study Investigating the Safety, Absorption, and Elimination of MB04, a New Compound That May Potentially be Used in the Treatment of Autoimmune Disorders","status":"COMPLETED","sponsor":"mAbxience Research S.L.","startDate":"2024-03-07","conditions":"Healthy Volunteers","enrollment":141},{"nctId":"NCT03294954","phase":"PHASE1","title":"GD2 Specific CAR and Interleukin-15 Expressing Autologous NKT Cells to Treat Children With Neuroblastoma","status":"RECRUITING","sponsor":"Baylor College of Medicine","startDate":"2018-01-18","conditions":"Neuroblastoma","enrollment":70},{"nctId":"NCT07138898","phase":"PHASE2","title":"Immunosuppressant Management in Rheumatology Patients Undergoing Elective Total Shoulder Arthroplasty","status":"NOT_YET_RECRUITING","sponsor":"NYU Langone Health","startDate":"2025-09","conditions":"Rheumatic Disease","enrollment":80},{"nctId":"NCT03414502","phase":"PHASE3","title":"Treatment of Rheumatoid Arthritis With DMARDs: Predictors of Response","status":"RECRUITING","sponsor":"University of Nebraska","startDate":"2007-12-10","conditions":"Rheumatoid Arthritis","enrollment":400},{"nctId":"NCT04891640","phase":"NA","title":"Biologic Abatement and Capturing Kids' Outcomes and Flare Frequency in Juvenile Spondyloarthritis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Children's Hospital of Philadelphia","startDate":"2021-11-11","conditions":"Juvenile Spondyloarthritis","enrollment":164},{"nctId":"NCT02713997","phase":"PHASE4","title":"Anti-inflammatory Therapy to Improve Outcomes After TPIAT","status":"COMPLETED","sponsor":"University of Minnesota","startDate":"2016-12","conditions":"Pancreatitis, Chronic; Diabetes; Transplant","enrollment":43},{"nctId":"NCT02714634","phase":"PHASE4","title":"Clinical Trial Evaluating Methotrexate or Leflunomide + Targeted Therapy Versus Methotrexate or Leflunomide + Sulfasalazine + Hydroxychloroquine in Patients With Rheumatoid Arthritis and Insufficient Response to Methotrexate or Leflunomide","status":"RECRUITING","sponsor":"University Hospital, Strasbourg, France","startDate":"2016-03-30","conditions":"Rheumatoid Arthritis, Insufficient Response to Methotrexate or Leflunomide","enrollment":286},{"nctId":"NCT04973566","phase":"PHASE1","title":"A Study of Nipocalimab With Co-administration of Etanercept or Hydroxychloroquine in Healthy Participants","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2021-08-31","conditions":"Healthy","enrollment":48},{"nctId":"NCT04254627","phase":"PHASE1","title":"TNF and Glucocorticoid Antagonist for GWI Associated Multi-symptom Disease Homeostasis Reset","status":"ACTIVE_NOT_RECRUITING","sponsor":"Nova Southeastern University","startDate":"2021-09-24","conditions":"Gulf War Illness","enrollment":20},{"nctId":"NCT04118556","phase":"PHASE2","title":"Decidua Stroma Cells for Steroid Resistent Acute Graft-versus-host Disease After Allo-HSCT","status":"RECRUITING","sponsor":"Mats Remberger","startDate":"2021-12-01","conditions":"GVHD, Acute","enrollment":50},{"nctId":"NCT00679042","phase":"PHASE3","title":"Islet Transplantation in Type 1 Diabetic Patients Using the University of Illinois at Chicago (UIC) Protocol","status":"ACTIVE_NOT_RECRUITING","sponsor":"CellTrans Inc.","startDate":"2007-09-05","conditions":"Type 1 Diabetes Mellitus","enrollment":21},{"nctId":"NCT03728478","phase":"PHASE3","title":"STep-up and Step-down Therapeutic Strategies in Childhood ARthritiS","status":"RECRUITING","sponsor":"Istituto Giannina Gaslini","startDate":"2019-05-29","conditions":"Oligoarthritis, Juvenile, Polyarthritis, Juvenile, Rheumatoid Factor Negative","enrollment":260},{"nctId":"NCT04725422","phase":"","title":"CHronic Nonbacterial Osteomyelitis International Registry","status":"RECRUITING","sponsor":"Seattle Children's Hospital","startDate":"2018-08-01","conditions":"Chronic Nonbacterial Osteomyelitis, Chronic Recurrent Multifocal Osteomyelitis","enrollment":2000},{"nctId":"NCT03182426","phase":"PHASE1, PHASE2","title":"Stem Cell Mobilization (Plerixafor) and Immunologic Reset in Type 1 Diabetes (T1DM)","status":"COMPLETED","sponsor":"University of Alberta","startDate":"2017-08-15","conditions":"Diabetes Mellitus, Type 1","enrollment":22},{"nctId":"NCT02451748","phase":"PHASE4","title":"IL-7 and IL-7R Expression in RA Patients With Active vs. Inactive Disease Treated With DMARD or CIMZIA","status":"COMPLETED","sponsor":"University of Illinois at Chicago","startDate":"2015-08","conditions":"Rheumatoid Arthritis","enrollment":32},{"nctId":"NCT02464878","phase":"PHASE2","title":"Multicenter Trial of the Effect of AAT on Islet Transplant Engraftment and Durability After Renal Transplant","status":"COMPLETED","sponsor":"Massachusetts General Hospital","startDate":"2017-01","conditions":"Kidney Transplant, Type 1 Diabetes","enrollment":2},{"nctId":"NCT03636373","phase":"PHASE4","title":"Pilot Study Evaluating The Efficacy Of Etanercept In Acute Gout","status":"TERMINATED","sponsor":"Rutgers, The State University of New Jersey","startDate":"2019-10-25","conditions":"Gout Attack","enrollment":5},{"nctId":"NCT02471144","phase":"PHASE3","title":"Pediatric Study in Children and Adolescents With Severe Plaque Psoriasis","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2015-09-29","conditions":"Chronic Severe Plaque-type Psoriasis","enrollment":162},{"nctId":"NCT05925166","phase":"NA","title":"Recombinant Human Tumor Necrosis Factor-α Receptor Ⅱ Fusion Protein in the Treatment of Acute Gout","status":"NOT_YET_RECRUITING","sponsor":"Lihua Duan","startDate":"2023-09-01","conditions":"Acute Gout","enrollment":100},{"nctId":"NCT00841789","phase":"PHASE2","title":"A Randomized, Double Blind, Placebo Controlled Study of Etanercept in Children With Kawasaki Disease","status":"COMPLETED","sponsor":"Michael Portman","startDate":"2009-03","conditions":"Mucocutaneous Lymph Node Syndrome, Kawasaki Disease","enrollment":205},{"nctId":"NCT00730392","phase":"PHASE1, PHASE2","title":"Etanercept in New Onset Type 1 Diabetes","status":"COMPLETED","sponsor":"State University of New York at Buffalo","startDate":"2002-10","conditions":"Type 1 Diabetes","enrollment":18},{"nctId":"NCT01421069","phase":"PHASE3","title":"Extension Study Evaluating Etanercept in 3 Subtypes of Childhood Arthritis","status":"COMPLETED","sponsor":"Pfizer","startDate":"2011-10-10","conditions":"Juvenile Idiopahtic Arthritis","enrollment":109},{"nctId":"NCT04610476","phase":"PHASE3","title":"Impact of Tapering Immunosuppressants on Maintaining Minimal Disease Activity in Adult Subjects With Psoriatic Arthritis","status":"UNKNOWN","sponsor":"University of Erlangen-Nürnberg Medical School","startDate":"2020-10-19","conditions":"Psoriatic Arthritis, Withdrawal, Reduction","enrollment":270},{"nctId":"NCT02374021","phase":"PHASE4","title":"Treatments Against RA and Effect on FDG-PET/CT","status":"COMPLETED","sponsor":"Brigham and Women's Hospital","startDate":"2016-07","conditions":"Arthritis, Rheumatoid","enrollment":159},{"nctId":"NCT05320159","phase":"","title":"Treatment Effectiveness Among Psoriasis Patients Treated With Cosentyx (Secukinumab)","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2021-02-03","conditions":"Psoriasis","enrollment":17743},{"nctId":"NCT00783536","phase":"PHASE4","title":"A Multicenter Study to Compare the Efficacy and Safety of the Combination of Etanercept and Methotrexate in Treatment of Rheumatoid Arthritis","status":"WITHDRAWN","sponsor":"Wyeth is now a wholly owned subsidiary of Pfizer","startDate":"2008-11","conditions":"Rheumatoid Arthritis","enrollment":""},{"nctId":"NCT02821026","phase":"PHASE1, PHASE2","title":"Omental Islet Transplant","status":"COMPLETED","sponsor":"University of Alberta","startDate":"2016-05","conditions":"Type 1 Diabetes","enrollment":4},{"nctId":"NCT01690299","phase":"PHASE3","title":"Phase 3b Safety and Efficacy Study of Apremilast to Treat Moderate to Severe Plaque-plaque Psoriasis","status":"COMPLETED","sponsor":"Amgen","startDate":"2012-10-01","conditions":"Psoriasis, Psoriatic Arthritis","enrollment":250},{"nctId":"NCT01729754","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety/Tolerability of Subcutaneous Tildrakizumab (SCH 900222/MK-3222) in Participants With Moderate-to-Severe Chronic Plaque Psoriasis Followed by a Long-term Extension Study (MK-3222-011)","status":"COMPLETED","sponsor":"Sun Pharmaceutical Industries Limited","startDate":"2013-02-05","conditions":"Plaque Psoriasis","enrollment":1090},{"nctId":"NCT01936688","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety/Tolerability of Subcutaneous MK-3222 in Participants With Moderate-to-Severe Chronic Plaque Psoriasis (MK-3222-012)","status":"WITHDRAWN","sponsor":"Sun Pharmaceutical Industries Limited","startDate":"2013-09","conditions":"Plaque-type Psoriasis","enrollment":""},{"nctId":"NCT00245960","phase":"PHASE4","title":"Study Evaluating Etanercept on Skin and Joint Disease in Psoriatic Arthritis","status":"COMPLETED","sponsor":"Wyeth is now a wholly owned subsidiary of Pfizer","startDate":"2005-12-27","conditions":"Psoriatic Arthritis","enrollment":752},{"nctId":"NCT05164198","phase":"PHASE4","title":"REduCed Dose of TNFi in Patients With Ankylosing SpondyliTis (RECAST)","status":"UNKNOWN","sponsor":"Hanyang University Seoul Hospital","startDate":"2022-01-15","conditions":"Ankylosing Spondylitis, Axial Spondyloarthritis","enrollment":448},{"nctId":"NCT05119452","phase":"NA","title":"Screening for Flare After b/tsDMARD Discontinuation in Rheumatoid Arthritis","status":"UNKNOWN","sponsor":"Medical University of Vienna","startDate":"2022-03","conditions":"Rheumatoid Arthritis","enrollment":85},{"nctId":"NCT00224874","phase":"PHASE2","title":"Treatment for Acute Graft-Versus-Host Disease (BMT CTN 0302)","status":"COMPLETED","sponsor":"National Heart, Lung, and Blood Institute (NHLBI)","startDate":"2005-09","conditions":"Graft vs Host Disease, Immune System Disorders","enrollment":180},{"nctId":"NCT05051137","phase":"","title":"Real-World Emulation of the SWEFOT Trial","status":"COMPLETED","sponsor":"Karolinska Institutet","startDate":"2006-01-12","conditions":"Rheumatoid Arthritis","enrollment":509},{"nctId":"NCT02092467","phase":"PHASE4","title":"Safety Study Of Tofacitinib Versus Tumor Necrosis Factor (TNF) Inhibitor In Subjects With Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Pfizer","startDate":"2014-03-14","conditions":"Arthritis, Rheumatoid","enrollment":4372},{"nctId":"NCT00566813","phase":"PHASE1, PHASE2","title":"Islet Transplantation in Type 1 Diabetic Patients Using the Edmonton Protocol of Steroid Free Immunosuppression","status":"COMPLETED","sponsor":"University of Illinois at Chicago","startDate":"2004-11","conditions":"Diabetes Mellitus, Type 1","enrollment":10},{"nctId":"NCT02464033","phase":"PHASE2","title":"EDCR Study - Etanercept Diamyd Combination Regimen -Open Trial to Evaluate Safety in Children With Type 1 Diabetes","status":"COMPLETED","sponsor":"Johnny Ludvigsson","startDate":"2015-05","conditions":"Diabetes Mellitus, Type 1","enrollment":20},{"nctId":"NCT01358578","phase":"PHASE3","title":"Safety and Efficacy of Secukinumab Compared to Etanercept in Subjects With Moderate to Severe, Chronic Plaque-Type Psoriasis","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2011-06","conditions":"Chronic Plaque Psoriasis","enrollment":1306},{"nctId":"NCT01764321","phase":"","title":"Noninterventional Examination of Subcutaneous (sc) Tumor Necrosis Factor (TNF) Inhibitors","status":"COMPLETED","sponsor":"UCB Pharma SA","startDate":"2012-12","conditions":"Rheumatoid Arthritis","enrollment":1723},{"nctId":"NCT00808210","phase":"PHASE2","title":"A Study to Evaluate Ocrelizumab in Combination With Methotrexate Compared With Infliximab Plus Methotrexate in Patients With Active Rheumatoid Arthritis Currently Responding Inadequately to Etanercept or Adalimumab","status":"TERMINATED","sponsor":"Genentech, Inc.","startDate":"2009-03-05","conditions":"Rheumatoid Arthritis","enrollment":28},{"nctId":"NCT02755194","phase":"","title":"\"Drugs in Lactation\" Analysis Consortium","status":"TERMINATED","sponsor":"The Hospital for Sick Children","startDate":"2014-09","conditions":"Lactation","enrollment":68},{"nctId":"NCT04115423","phase":"","title":"A Retrospective Cohort Study on the Risk of Serious Infections in Rheumatoid Arthritis Patients Receiving Tocilizumab","status":"UNKNOWN","sponsor":"Sungkyunkwan University","startDate":"2020-04-01","conditions":"Infection, Rheumatoid Arthritis","enrollment":9508},{"nctId":"NCT01646177","phase":"PHASE3","title":"A Study in Participants With Moderate to Severe Psoriasis (UNCOVER-3)","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2012-07-28","conditions":"Psoriasis","enrollment":1346},{"nctId":"NCT01597245","phase":"PHASE3","title":"A Phase 3 Study in Participants With Moderate to Severe Psoriasis (UNCOVER-2)","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2012-05-18","conditions":"Psoriasis","enrollment":1224},{"nctId":"NCT02960035","phase":"PHASE4","title":"A Study of the MASEI in the Treatment of Anti-TNF Blocker to Peripheral Tendonitis in Patients With Spondyloarthritis","status":"COMPLETED","sponsor":"Sun Yat-sen University","startDate":"2014-04","conditions":"Spondyloarthropathy","enrollment":96},{"nctId":"NCT01100034","phase":"","title":"Study Evaluating the Safety and Effectiveness of Etanercept for the Treatment of Pediatric Psoriasis","status":"COMPLETED","sponsor":"Pfizer","startDate":"2010-11-19","conditions":"Psoriasis","enrollment":72},{"nctId":"NCT04077957","phase":"PHASE4","title":"Treat-to-target Strategy in Ankylosing Spondylitis Using Etanercept and Conventional Synthetic DMARDs","status":"UNKNOWN","sponsor":"Nanfang Hospital, Southern Medical University","startDate":"2019-10-07","conditions":"Ankylosing Spondylitis, Spondyloarthritis","enrollment":100},{"nctId":"NCT00078806","phase":"PHASE3","title":"Safety and Efficacy Study of Etanercept (Enbrel®) In Children With Systemic Onset Juvenile Rheumatoid Arthritis","status":"TERMINATED","sponsor":"Amgen","startDate":"2001-06-04","conditions":"Juvenile Rheumatoid Arthritis","enrollment":19},{"nctId":"NCT02433184","phase":"PHASE4","title":"Very Early Versus Delayed Etanercept in Patients With RA","status":"COMPLETED","sponsor":"University of Leeds","startDate":"2011-07","conditions":"Rheumatoid Arthritis","enrollment":120},{"nctId":"NCT03780959","phase":"PHASE2, PHASE3","title":"Safety and Efficacy of Etanercept (Recombinant Human Tumor Necrosis Factor Receptor Fusion Protein [TNFR:Fc]) in Children With Juvenile Rheumatoid Arthritis (JRA)","status":"COMPLETED","sponsor":"Amgen","startDate":"1997-05-01","conditions":"Juvenile Rheumatoid Arthritis","enrollment":69},{"nctId":"NCT00078819","phase":"PHASE3","title":"Etanercept (Enbrel®) in Psoriasis - Pediatrics","status":"COMPLETED","sponsor":"Amgen","startDate":"2004-09-08","conditions":"Psoriasis","enrollment":211},{"nctId":"NCT02986139","phase":"PHASE3","title":"Study to Assess the Injection Site Pain Associated With a New Etanercept Formulation in Adults With Rheumatoid Arthritis or Psoriatic Arthritis","status":"COMPLETED","sponsor":"Amgen","startDate":"2016-11-29","conditions":"Arthritis, Rheumatoid; Arthritis, Psoriatic","enrollment":111},{"nctId":"NCT00434811","phase":"PHASE3","title":"Islet Transplantation in Type 1 Diabetes","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2006-10","conditions":"Type 1 Diabetes Mellitus","enrollment":48},{"nctId":"NCT01241591","phase":"PHASE3","title":"A Phase 3, Multi Site, Randomized, Double Blind, Placebo Controlled Study Of The Efficacy And Safety Comparing CP- 690,550 And Etanercept In Subjects With Moderate To Severe Chronic Plaque Psoriasis","status":"COMPLETED","sponsor":"Pfizer","startDate":"2010-11","conditions":"Psoriasis","enrollment":1101},{"nctId":"NCT02570750","phase":"","title":"The Effect Of Smoking Status Of The Patient On The Success Of Etanercept Therapy In Psoriasis","status":"COMPLETED","sponsor":"Pfizer","startDate":"2015-05-07","conditions":"Chronic Plaque Psoriasis","enrollment":183},{"nctId":"NCT02202837","phase":"","title":"Study With Etanercept Focusing on Remission and Predictability of Remission in Real Life Clinical Practice","status":"COMPLETED","sponsor":"Pfizer","startDate":"2014-08-12","conditions":"Rheumatoid Arthritis","enrollment":157},{"nctId":"NCT02202850","phase":"","title":"Defining Remission With Etanercept in AS in Real Life Clinical Practice","status":"COMPLETED","sponsor":"Pfizer","startDate":"2014-08-12","conditions":"Ankylosing Spondylitis","enrollment":84},{"nctId":"NCT02638259","phase":"PHASE3","title":"Comparative Efficacy and Safety Study of GP2015 and Enbrel® in Patients With Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Sandoz","startDate":"2015-02-21","conditions":"Rheumatoid Arthritis","enrollment":376},{"nctId":"NCT01901185","phase":"PHASE3","title":"Study to Evaluate the Ability of Subjects With Rheumatoid Arthritis or Psoriatic Arthritis to Effectively Use a Reusable Autoinjector to Self-inject Etanercept","status":"COMPLETED","sponsor":"Amgen","startDate":"2013-06-11","conditions":"Rheumatoid Arthritis, Psoriatic Arthritis","enrollment":77},{"nctId":"NCT01235442","phase":"PHASE3","title":"Evaluate Efficacy, and Safety of Topical Therapy and Etanercept in Subjects With Moderate to Severe Plaque Psoriasis","status":"COMPLETED","sponsor":"Amgen","startDate":"2010-09","conditions":"Psoriasis","enrollment":592},{"nctId":"NCT02862574","phase":"PHASE2","title":"Andecaliximab as Add-On Therapy to a Tumor Necrosis Factor Inhibitor and Methotrexate Regimen in Adults With Moderately to Severely Active Rheumatoid Arthritis","status":"TERMINATED","sponsor":"Gilead Sciences","startDate":"2016-12-15","conditions":"Rheumatoid Arthritis","enrollment":15},{"nctId":"NCT01934933","phase":"PHASE4","title":"Etanercept and Celecoxib Alone/Combined Treatment in Effectiveness and Safety of Active Ankylosing Spondylitis","status":"COMPLETED","sponsor":"Sun Yat-sen University","startDate":"2014-09-24","conditions":"Ankylosing Spondylitis","enrollment":150},{"nctId":"NCT03496831","phase":"","title":"Predicting Hospitalized Infection in Patients With Chronic Inflammatory Arthritis Treated With Biological Drugs","status":"COMPLETED","sponsor":"Simon Krabbe","startDate":"2006-01-01","conditions":"Rheumatoid Arthritis, Spondyloarthritis, Psoriatic Arthritis","enrollment":7500},{"nctId":"NCT00285779","phase":"PHASE2","title":"Use of Etanercept in the Treatment of Moderate to Severe Lichen Planus","status":"TERMINATED","sponsor":"Stanford University","startDate":"2006-08","conditions":"Lichen Planus","enrollment":27},{"nctId":"NCT01276314","phase":"NA","title":"Evaluation of TNF-α Blockade Effect in Patients With Severe Cutaneous Adverse Drug Reactions","status":"COMPLETED","sponsor":"Chang Gung Memorial Hospital","startDate":"2009-01","conditions":"Drug Hypersensitivity","enrollment":135},{"nctId":"NCT00031551","phase":"PHASE2","title":"Evaluation of Efficacy and Mechanisms of an Antiinflammatory Intervention for Chemotherapy Related Mucosal Injury","status":"TERMINATED","sponsor":"National Institute of Nursing Research (NINR)","startDate":"2002-03","conditions":"Stomatitis","enrollment":27},{"nctId":"NCT00201838","phase":"PHASE1, PHASE2","title":"Etanercept and Gemcitabine in Patients With Advanced, Chemotherapy Naive Pancreatic Adenocarcinoma","status":"COMPLETED","sponsor":"Ohio State University Comprehensive Cancer Center","startDate":"2001-07","conditions":"Pancreatic Neoplasms, Adenocarcinoma","enrollment":38},{"nctId":"NCT00888628","phase":"PHASE1, PHASE2","title":"Study of Islet Transplantation in Type 1 Diabetic Kidney Transplant Recipients","status":"COMPLETED","sponsor":"Massachusetts General Hospital","startDate":"2009-05","conditions":"Diabetes Mellitus, Type I","enrollment":7},{"nctId":"NCT00468117","phase":"PHASE3","title":"Efficacy of Islet After Kidney Transplantation","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2007-01","conditions":"Type 1 Diabetes Mellitus","enrollment":24},{"nctId":"NCT02330380","phase":"","title":"Comparative Effectiveness of Psoriasis Treatments on Systemic Inflammation","status":"COMPLETED","sponsor":"University Hospitals Cleveland Medical Center","startDate":"2013-04","conditions":"Psoriasis, Inflammation","enrollment":26},{"nctId":"NCT00825344","phase":"NA","title":"Preoperative Etanercept Before Inguinal Hernia Surgery","status":"COMPLETED","sponsor":"Johns Hopkins University","startDate":"2009-01","conditions":"Inguinal Hernia, Postoperative Pain","enrollment":77},{"nctId":"NCT03193203","phase":"PHASE1","title":"Pharmacokinetics, Safety, and Tolerability Study of the Autoinjector and Pre-filled Syringe of SB4 in Healthy Male Subjects","status":"COMPLETED","sponsor":"Samsung Bioepis Co., Ltd.","startDate":"2017-03-24","conditions":"Healthy","enrollment":50},{"nctId":"NCT00639717","phase":"PHASE2","title":"Addition of Etanercept and Extracorporeal Photopheresis (ECP) to Standard Graft-Versus-Host Disease (GVHD) Prophylaxis in Stem Cell Transplant","status":"COMPLETED","sponsor":"University of Michigan Rogel Cancer Center","startDate":"2009-03","conditions":"Graft Versus Host Disease","enrollment":48},{"nctId":"NCT01294397","phase":"PHASE1","title":"Effects of Denosumab on the Pharmacokinetics of Etanercept","status":"TERMINATED","sponsor":"Amgen","startDate":"2011-03","conditions":"Postmenopausal, Osteopenia, Rheumatoid Arthritis","enrollment":19},{"nctId":"NCT00118287","phase":"PHASE1, PHASE2","title":"Azacitidine and Etanercept in Treating Patients With Myelodysplastic Syndromes","status":"COMPLETED","sponsor":"Fred Hutchinson Cancer Center","startDate":"2005-04","conditions":"de Novo Myelodysplastic Syndromes, Previously Treated Myelodysplastic Syndromes, Secondary Myelodysplastic Syndromes","enrollment":32},{"nctId":"NCT01400516","phase":"PHASE4","title":"Teriparatide for Joint Erosions in Rheumatoid Arthritis: The TERA Trial","status":"COMPLETED","sponsor":"Brigham and Women's Hospital","startDate":"2011-08","conditions":"Rheumatoid Arthritis","enrollment":26},{"nctId":"NCT01230177","phase":"","title":"Etanercept (Enbrel) Special Investigation (Regulatory Post Marketing Commitment Plan)","status":"COMPLETED","sponsor":"Pfizer","startDate":"2011-05","conditions":"Arthritis, Rheumatoid","enrollment":3},{"nctId":"NCT00357903","phase":"PHASE3","title":"Open-Label Extension Treatment With Etanercept (TNFR:Fc) for Participating Patients in Etanercept (TNFR:Fc) Clinical Trials","status":"COMPLETED","sponsor":"Amgen","startDate":"1997-04","conditions":"Rheumatoid Arthritis","enrollment":639},{"nctId":"NCT00201682","phase":"PHASE1, PHASE2","title":"Etanercept and Rituximab in Patients With Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma","status":"COMPLETED","sponsor":"John Byrd","startDate":"2002-10","conditions":"Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma","enrollment":36},{"nctId":"NCT02274792","phase":"PHASE4","title":"Study to Assess the Immunogenicity and Safety of Etanercept Produced Using a Modified Process in Patients With Plaque Psoriasis","status":"COMPLETED","sponsor":"Amgen","startDate":"2015-01","conditions":"Plaque Psoriasis","enrollment":132},{"nctId":"NCT02999776","phase":"PHASE1","title":"Laser-assisted Topical Administration of Etanercept (Enbrel®) in Patients With Mild to Moderate Plaque-type Psoriasis","status":"UNKNOWN","sponsor":"Pantec Biosolutions AG","startDate":"2016-11","conditions":"Psoriatic Plaque","enrollment":30},{"nctId":"NCT01295151","phase":"PHASE4","title":"SWITCH Clinical Trial for Patients With Rheumatoid Arthritis Who Have Failed an Initial TNF-blocking Drug.","status":"COMPLETED","sponsor":"Julia Brown","startDate":"2011-08","conditions":"Rheumatoid Arthritis","enrollment":122},{"nctId":"NCT02878161","phase":"PHASE4","title":"Predictability Studies on the Efficacy of TNF-α Inhibitors in Chinese RA From \"Real World\"","status":"UNKNOWN","sponsor":"Fen Li","startDate":"2016-01","conditions":"Rheumatoid Arthritis","enrollment":240},{"nctId":"NCT02779114","phase":"PHASE3","title":"RETRO (REduction of Therapy in RA Patients in Ongoing Remission)","status":"UNKNOWN","sponsor":"University of Erlangen-Nürnberg Medical School","startDate":"2009-01","conditions":"Rheumatoid Arthritis","enrollment":318},{"nctId":"NCT02694770","phase":"PHASE2","title":"A Study Evaluating the Efficacy and Safety of Neihulizumab vs \"Conventional Treatment\" to Treat Sr-aGvHD","status":"WITHDRAWN","sponsor":"AbGenomics B.V Taiwan Branch","startDate":"2016-07","conditions":"Steroid-refractory aGvHD Subsequent to Allogeneic Hematopoietic Cell Transplantation","enrollment":""},{"nctId":"NCT00789997","phase":"PHASE2, PHASE3","title":"TNF-alpha Antagonists for AECOPD: A Randomized, Double-Blind, Placebo-Controlled Pilot Trial","status":"COMPLETED","sponsor":"Ottawa Hospital Research Institute","startDate":"2008-11","conditions":"COPD Exacerbation","enrollment":81},{"nctId":"NCT00434850","phase":"PHASE2","title":"Peritransplant Deoxyspergualin in Islet Transplantation in Type 1 Diabetes","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2006-10","conditions":"Diabetes Mellitus, Type 1","enrollment":14},{"nctId":"NCT02701205","phase":"PHASE3","title":"Safety and Efficacy Study of Etanercept (Qiangke®) to Treat Moderate to Severe Plaque Psoriasis","status":"UNKNOWN","sponsor":"Shanghai Celgen Bio-Pharmaceutical Co.,Ltd","startDate":"2015-01","conditions":"Plaque Psoriasis, Psoriasis","enrollment":216}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":4237,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"1=Etanercept","genericName":"1=Etanercept","companyName":"Amgen","companyId":"amgen","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Etanercept is a medication used to treat conditions such as rheumatoid arthritis, de novo myelodysplastic syndromes, previously treated myelodysplastic syndromes, secondary myelodysplastic syndromes, and nail psoriasis. It is compared to methotrexate and a placebo in clinical trials, and its efficacy and safety are evaluated in a randomized, double-blind study.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}